Gretchen Gignac, MD
Clinical Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MD, University of Pennsylvania School of Medicine
BA, University of Rochester

I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Chobanian and Avedisian School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.

Diversity, Equity, Inclusion and Accessibility

I am deeply committed to promoting diversity and inclusion in academia and medicine. I welcome and celebrate individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, disability, sexual orientation, veteran status, and national origin. I am a part of a dedicated team of healthcare professionals, researchers, students and staff that serves the communities of Boston and its surroundings. I have great pride working at a large academic medical center and safety-net hospital that shares my goal to provide equitable cutting edge clinical care and research opportunities to our patients. I am dedicated to continuing research, clinical and career mentorship for trainees at all levels at Chobanian and Avedisian School of Medicine and Boston Medical Center. My clinical research is focused on improving equity in prostate cancer care and these initiatives have been supported through grant funded research (e.g. DOD and NIH) and have resulted in peer reviewed publications.

Boston University
BU-BMC Cancer Center

Boston University
Evans Center for Interdisciplinary Biomedical Research

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 11/16/2015 (PI)
Millennium Pharmaceuticals, Inc.

A Randomized phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen to Cabazitaxel/Prednisone for second line chemotherapy in men with metastatic castrte resistant prostate cance
09/28/2012 - 08/13/2015 (PI)
OncoGenex Technologies, Inc

A phase 3, Randomized, Double-blind, controlled study of cabozantinib (XL184) vs. Prednisone in Metastatic castration resistant prostate cancer patients who have received prior cocetaxel and prior abi
10/19/2012 - 10/19/2014 (PI)
Exelixis, Inc

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

DFCI 21-575 - A Phase 2 study of avelumab, axitinib and palbociclib in metastatic renal cell carcinoma
03/21/2022 - 03/20/2024 (PI)
Dana Farber Cancer Institute

Precision Interception of Aggressive Prostate Cancer in African American Men
09/18/2018 - 08/31/2022 (PI)
Dana Farber Cancer Institute National Cancer Inst

12/03/2018 - 12/03/2021 (PI)
Bristol-Myers Squibb Company

SGN22E-003: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
10/02/2020 - 10/01/2021 (PI)
Seattle Genetics, Inc.

Racial Differences in Androgen Receptor Splice Variants in Men with Localized Prostate Cancer
03/01/2018 - 05/31/2021 (PI)
The General Hospital Corporation / MGH Dept of Defense


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Khosla H, Bhatt S, Wang MJ, Gignac G, Mittal K, Patel J. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis. J Oncol Pharm Pract. 2024 Jul; 30(5):941-944. PMID: 38470473
  2. Gunn CM, Gignac G, Hardy B, Zayhowski K, Pankowska M, Loo S, Wang C. Characterizing Referrals for Prostate Cancer Genetic Services in a Safety-Net Hospital. JCO Oncol Pract. 2023 Oct; 19(10):852-859.View Related Profiles. PMID: 37384869; DOI: 10.1200/OP.23.00055;
  3. Gunn CM, Li EX, Gignac GA, Pankowska M, Loo S, Zayhowski K, Wang C. Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care. Cancer Control. 2023; 30:10732748221143884.View Related Profiles. PMID: 36946278; PMCID: PMC10037728; DOI: 10.1177/10732748221143884;
  4. Jafari N, Chen A, Kolla M, Pompa IR, Qiu Y, Yu R, Llevenes P, Ennis CS, Mori J, Mahdaviani K, Halpin M, Gignac GA, Heaphy CM, Monti S, Denis GV. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv Cancer Biol Metastasis. 2022 Dec; 6.View Related Profiles. PMID: 36644690; PMCID: PMC9836031; DOI: 10.1016/j.adcanc.2022.100073;
  5. Quintiliani LM, Murray GF, Waite K, Salerno K, Gignac GA, Yuh D, Volandes A, Paasche-Orlow MK. "I'm in My Feelings Now": Examination of Advance Care Planning Video Declarations by People with Advanced Cancer from a Safety Net Hospital. J Palliat Med. 2023 Jan; 26(1):28-34.View Related Profiles. PMID: 35708552
  6. Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015.View Related Profiles. PMID: 35403746; PMCID: PMC11134172; DOI: 10.1002/pros.24351;
  7. Chua S, Qureshi MM, Boyd G, Gignac GA, Hirsch AE. Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB. Clin Genitourin Cancer. 2020 10; 18(5):e531-e542.View Related Profiles. PMID: 32220567
  8. Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019 Feb; 21(2):206-212.View Related Profiles. PMID: 29948974
  9. Kan CK, Qureshi MM, Gupta A, Agarwal A, Gignac GA, Bloch BN, Thoreson N, Hirsch AE. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):181-189.View Related Profiles. PMID: 29904743; PMCID: PMC6000162; DOI: 10.1016/j.adro.2017.12.002;
  10. Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8.View Related Profiles. PMID: 27515296; DOI: 10.1530/ERC-16-0222;
Showing 10 of 22 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 22 publications over 14 distinct years, with a maximum of 3 publications in 2009 and 2011 and 2022


Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Project Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

820 Harrison Ave
Boston MA 02118
Google Map

Gignac's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department